Metastatic castration-resistant prostate cancer
Zachary BessetteNext-Generation Imaging | September 13, 2023
Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative.
Read More
Zachary BessettemCRPC | September 6, 2023
SNMMI convened an autonomous workgroup to review prospective phase 2/3 clinical trials that used 177Lu-PSMA-617.
Emily MenendezRLT-PSMA | August 31, 2023
A PSA decrease ≥30% after the first 2 cycles of 177Lu PSMA can serve as an early marker of response in clinical practice.
Emily MenendezmCRPC | August 31, 2023
As mCRPC cells are deficient in retinoblastoma proteins, they have a hypersensitivity to taxanes such as cabazitaxel.
Emily MenendezmCRPC | August 29, 2023
The trial’s 2 primary end points were PFS and overall survival, with a secondary end point of objective response rate.
Catherine H. Marshall, MD, MPHmCRPC | August 22, 2023
Drs. Marshall, Reimers, and Dorff discuss toxicities from single-agent and combination-based HR inhibitors.
Catherine H. Marshall, MD, MPHmCRPC | August 22, 2023
Drs. Marshall, Reimers, and Dorff discuss PARP inhibitor strategies for BRCA-mutated patients throughout the care continuum.
Zachary BessettemCRPC | August 22, 2023
Foundation Medicine’s comprehensive genomic profiling test identifies mCRPC harboring BRCA1/2-positive mutations.
Zachary BessettemCRPC | August 14, 2023
The FDA granted approval to AKEEGA given with prednisone for patients with BRCA-positive mCRPC.
Emily MenendezProstate Cancer | August 2, 2023
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
Emily MenendezRLT-PSMA | July 5, 2023
The VISION trial assigned patients to receive either [177Lu]Lu-PSMA-617 plus standard of care or standard of care alone.
Zachary BessetteSNMMI 2023 | June 27, 2023
New research identified genomic features and post-therapeutic SPECT/CT parameters as predictors of response to Pluvicto.
Zachary BessettemCRPC | June 21, 2023
The US FDA granted approval to talazoparib in combination with enzalutamide for adult patients with HRR-mutated mCRPC.
Emily MenendezProstate Cancer | June 20, 2023
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.
Karim Fizazi, MD, PhDASCO 2023 | June 5, 2023
Drs. Fizazi and Wallis detail the latest updates regarding TALAPRO-2 for patients with mCRPC and HRR gene alterations.
Andrew Armstrong, MD, MScASCO 2023 | June 4, 2023
Drs. Armstrong and Wallis discuss the design of an AI-derived pathology-based biomarker for localized high-risk prostate.
Emily MenendezASCO 2023 | June 3, 2023
The combination treatment of dual-PSMA targeting with mAb and SML is feasible, and a follow-up study is in progress.
Emily MenendezmCRPC | June 1, 2023
The FDA has approved the combination treatment of olaparib with abiraterone and prednisone for BRCA-mutated mCRPC.
Emily MenendezASCO 2023 | May 31, 2023
Results outlined patient-reported outcomes from the TALAPRO-2 trial on first-line talazoparib plus enzalutamide for mCRPC.
Tanya Dorff, MDmCRPC | May 30, 2023
Dr. Dorff explains how the prognostic model from the CALGB 90401 trial provides accurate information to patients with mCRPC.